NEW - Check out GRx+Biosims 2018 now

Just Released!

The 10th edition of the Generic Drug Access & Savings in the United States report.

Read 2018 Report
Register for GRx+Biosims 2018

We’re uniting the power of innovation, science and policy to increase patient access to generic and biosimilar medicines.

Register Now
#PassCREATES

Congress can pass the CREATES Act, which will stop the anti-competitive practices that are costing patients billions.

Learn More
Read the Biosimilars Council's New White Paper

Delivering More-Affordable, Innovative Medicines to America’s Patients

Read More
Skyrocketing Drug Prices Are a Threat to Everyone

Use this infographic to learn how generics and biosimilars are a remedy to sky-high health care costs.

Read Blog
Customize Your GRx+Biosims Experience

Create a customized curriculum with AAM's learning tracks to help further your goals at GRx+Biosims.

View Agenda

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of current drugs and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Society

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable medicines. Learn More

About Us

The Association for Accessible Medicines, formerly the Generic Pharmaceutical Association, improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Jul 19, 2018 | Allen Goldberg

AAM Statement on Importation Task Force

AAM Statement on FDA’s Biosimilars Action - Press Release Header

Jul 18, 2018 | Allen Goldberg

AAM Statement on FDA’s Biosimilars Action Plan

Video

Jul 16, 2018 | Erica Klinger

Highlights from Craig Burton on the Newly Released 2018 Generic Drug Access & Savings Report

Trump & HHS Blueprint to Lower Drug Prices (RFI)

Jul 16, 2018 | Allen Goldberg

AAM Provides Comments in Response to Administration’s Blueprint on Drug Pricing

2018 AAM Access and Savings in the U.S. Report

Jul 10, 2018 | Rachel Schwartz

Generic Drug Competition Lowers Prescription Cost to $6 on Average, Study Finds

2018 Generic Drug Access and Savings Report Cover

Jun 28, 2018 | Rachel Schwartz

2018 Generic Drug Access and Savings Report